OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Carlo-Stella on Updated Results on RG6234 Activity in R/R Multiple Myeloma

December 23rd 2022

Carmelo Carlo-Stella, MD, PhD, discusses updated results from a phase 1 dose-escalation study of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.

Experts on Second-Line Treatment Options for EGFR TKI-Resistant NSCLC

December 23rd 2022

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss second-line treatment options for patients with non—small cell lung cancer who progressed on first-line EGFR-directed tyrosine kinase inhibitors.

Experts on the Evaluation of CEACAM5-Targeted Therapy in NSCLC

December 23rd 2022

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the evaluation of CEACAM5 biomarker testing in non–small cell lung cancer.

Experts on the Use of ADCs in HER2-Mutated NSCLC Treatment

December 23rd 2022

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the use of antibody-drug conjugates (ADCs) in HER2-mutated non–small cell lung cancer.

Dr. Tarantino on the Impact of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

December 23rd 2022

Paolo Tarantino, MD, discusses the impact of the phase 3 DESTINY-Breast04 trial in the treatment of HER2-low breast cancer.

Dr. Jabbour on the Evaluation of Olverembatinib in Ponatinib-Resistant CML and Ph+ ALL

December 23rd 2022

Elias Jabbour, MD, discusses the evaluation of olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Dr. Shiller on the Role of Trastuzumab Deruxtecan in HER2+ Breast Cancer

December 23rd 2022

Michelle Shiller, DO, AP/CP, MGP, discusses the role of trastuzumab deruxtecan in patients with HER2-positive breast cancer.

Dr. Kumar on Updated Data from the MAIA Trial in Newly Diagnosed Multiple Myeloma

December 23rd 2022

Shaji Kumar, MD, discusses the updated data from the phase 3 MAIA trial in newly diagnosed multiple myeloma.

Dr. Oh on the Anemia Benefit of Pacritinib in Myelofibrosis

December 23rd 2022

Stephen T. Oh, MD, PhD, discusses the anemia benefit of pacritinib in patients with myelofibrosis.

Dr. Iyer on Unmet Needs for Patients With TSC1/2-mutated Solid Tumors

December 23rd 2022

Gopa Iyer, MD, discusses the unmet needs for patients with solid tumors harboring TSC1/2 mutations.

Dr. Shaughnessy on the Potential of the FELIX Trial to Address Unmet Needs in B-ALL

December 23rd 2022

Paul J. Shaughnessy, MD, discusses the potential of the phase 1/2 FELIX trial to address unmet needs in relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Chaudhary on the Correlation of PD-L2 Status and PFS Rates in ER+ Breast Cancer

December 21st 2022

Lubna N. Chaudhary, MD, discusses the correlation between PD-L2 status and progression-free survival rates in treatment-naïve estrogen receptor–positive breast cancer.

Dr. Gadi on the Investigation of AMUN-003 in TNBC

December 21st 2022

Vijayakrishna Gadi, MD, PhD, discusses the investigation of AMUN-003 in triple-negative breast cancer.

Dr. Bardia on the Ongoing Investigation of Oral SERDs in ER+/HER2- Breast Cancer

December 19th 2022

Aditya Bardia, MD, MPH, discusses the investigation of oral selective estrogen receptor degraders in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Dr. Kaklamani on the Evolution of Oral SERDs in ER+ Breast Cancer

December 19th 2022

Virginia G. Kaklamani, MD, discusses the evolution of oral selective estrogen receptor degraders in estrogen receptor-positive breast cancer.

Dr. Rampal on the Importance of Clinical Trial Enrollment in Myelofibrosis

December 19th 2022

Raajit K. Rampal, MD, PhD, discusses the importance of clinical trial enrollment in patients with myelofibrosis.

Dr. Oh on Pacritinib in Myelofibrosis

December 19th 2022

Stephen T. Oh, MD, PhD, discusses the benefits of pacritinib in patients with myelofibrosis.

Dr. Palmer on Symptom Burden in Myelofibrosis With Thrombocytopenia

December 19th 2022

Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.

Dr. Burke on the Underrepresentation of Elderly Patients in Clinical Trials for Lymphoma

December 19th 2022

John M. Burke, MD, discusses the underrepresentation of elderly patients in clinical trials for lymphoma.

Dr. Niemann on Ibrutinib Plus Venetoclax Vs Chlorambucil and Obinutuzumab in Mutated CLL

December 19th 2022

Carsten Niemann, MD, PhD, discusses ibrutinib plus venetoclax vs chlorambucil and obinutuzumab in mutated chronic lymphocytic leukemia.